| Literature DB >> 31938633 |
Sainath Reddy Kaladi1, Veeresh Tegginmani2, Manoosha M3, Sumana Mitta4, Pradeep Chigadani4, Anitha Viswanadhan5.
Abstract
Background and objectives Pain is the primary reason that dental patients seek endodontic therapy. The inferior alveolar nerve block (IANB) is the most frequently used mandibular injection technique for achieving local anesthesia for endodontic treatment. However, the IANB does not always result in successful pulpal anesthesia. Therefore, the purpose of this study was to determine the effects of preoperative administration of both ibuprofen and ketorolac on the efficacy of the IANB in patients with irreversible pulpitis. Methods A total of 60 patients diagnosed with irreversible pulpits of a mandibular posterior tooth randomly received identical capsules of either 400 mg ibuprofen or 20 mg ketorolac or a placebo 1 hour before the administration of a conventional IANB. Access was initiated after profound lip numbness was achieved. Success was defined as no, mild, moderate, or severe pain (verbal rating scale recordings) on accessing the dentin, pulp, and debridement. Results Ketorolac was associated with superior efficacy in pain reduction when compared with ibuprofen and placebo in all parameters, namely the dentin, pulp, and canal debridement. Interpretation and conclusion In conclusion, for mandibular posterior teeth, a preoperative dose of 400 mg of ibuprofen or 20 mg of ketorolac showed a statistically significant increase in the success of the IANB in patients with irreversible pulpitis.Entities:
Keywords: ianb; nsaid’s; pre- operative pain; verbal rating scale
Year: 2019 PMID: 31938633 PMCID: PMC6952035 DOI: 10.7759/cureus.6346
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Mean age of study population according to group and gender
| Group | Gender | N | Minimum | Maximum | Mean | Standard Deviation |
| Ketorolac Group | Male | 13 | 24 | 38 | 31.46 | 4.156 |
| Female | 7 | 29 | 39 | 33.71 | 3.147 | |
| Ibuprofen group | Male | 11 | 27 | 37 | 32.55 | 3.671 |
| Female | 9 | 24 | 36 | 29.22 | 4.969 | |
| Placebo Group | Male | 13 | 24 | 39 | 29.92 | 4.974 |
| Female | 7 | 27 | 37 | 32.29 | 3.450 |
Frequency distribution of dentin VRS score
VRS, verbal rating scale; **Highly significant (p < 0.01)
| Score | Ketorolac Group | Ibuprofen Group | Placebo Group | |||
| Frequency | Percentage | Frequency | Percentage | Frequency | Percentage | |
| 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2 | 16 | 80.0 | 0 | 0 | 0 | 0 |
| 3 | 4 | 20.0 | 16 | 80.0 | 10 | 50.0 |
| 4 | 0 | 0.0 | 4 | 20.0 | 10 | 50.0 |
| Total | 20 | 100.0 | 20 | 100.0 | 20 | 100.0 |
| Median | 2 | 3 | 4 | |||
| Chi-square value | 50.05 | P value | <0.001** | |||
Frequency distribution of pulp VRS score
VRS, verbal rating scale; *Statistically significant (p < 0.05)
| Score | Ketorolac Group | Ibuprofen Group | Placebo Group | |||
| Frequency | Percentage | Frequency | Percentage | Frequency | Percentage | |
| 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2 | 2 | 10.0 | 0 | 0 | 0 | 0 |
| 3 | 10 | 50.0 | 11 | 55.0 | 4 | 20.0 |
| 4 | 8 | 40.0 | 9 | 45.0 | 16 | 80.0 |
| Total | 20 | 100.0 | 20 | 100.0 | 20 | 100.0 |
| Median | 3 | 3 | 4 | |||
| Chi sq | 10.895 | P-value | 0.028* | |||
Frequency distribution of debridement VRS score
VRS, verbal rating scale; **Highly significant (p < 0.01)
| Score | Ketorolac Group | Ibuprofen Group | Placebo Group | |||
| Frequency | Percentage | Frequency | Percentage | Frequency | Percentage | |
| 1 | 19 | 95.0 | 9 | 45.0 | 0 | 0 |
| 2 | 1 | 5.0 | 11 | 55.0 | 3 | 15.0 |
| 3 | 0 | 0.0 | 0 | 0.0 | 17 | 85.0 |
| 4 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Total | 20 | 100.0 | 20 | 100.0 | 20 | 100.0 |
| Median | 1 | 2 | 3 | |||
| Chi sq | 64.557 | P-value | <0.001** | |||
Intragroup comparison of pain scores at various locations
**Statistically significant (p < 0.01), *Statistically significant (p < 0.05); NS, not significant (p > 0.05)
| Comparison | Ketorolac group | Ibuprofen group | Placebo group | |||
| Z value | Sig | Z value | Sig | Z value | Sig | |
| Baseline vs Dentin | -4.072 | <0.001** | -2.5 | 0.012* | -1.508 | 0.132 NS |
| Baseline vs Pulp | -2.399 | 0.016* | -2.236 | 0.025* | -0.333 | 0.739 NS |
| Baseline vs Debridement | -4.179 | <0.001** | -3.976 | <0.001** | -4.243 | <0.001** |
| Dentin vs Pulp | -3.704 | <0.001** | -1.387 | 0.166 NS | -2.121 | 0.034* |
| Dentin vs Debridement | -4.065 | <0.001** | -4.028 | <0.001** | -3.127 | 0.002** |
| Pulp vs Debridement | -3.993 | <0.001** | -3.976 | <0.001** | -3.755 | <0.001** |
Intergroup comparison of VAS scores
VAS, visual analogue scale; **Statistically highly significant (p < 0.01); NS, not significant (p > 0.05)
| Intragroup Comparison | ||||||||||||
| Intergroup comparison | Group | N | Baseline | Dentin | Pulp | Debridement | ||||||
| Mean Rank | Median | Mean Rank | Median | Mean Rank | Median | Mean Rank | Median | Friedman value | Sig | |||
| Ketorolac Group | 20 | 33.00 | 4 | 13.10 | 2 (50%) | 25.25 | 3 (25%) | 15.58 | 1 (75%) | 54.326 | <0.001** | |
| Ibuprofen Group | 20 | 28.50 | 4 | 35.90 | 3 (25%) | 28.05 | 3 (25%) | 26.33 | 2 (50%) | 46.053 | <0.001** | |
| Placebo Group | 20 | 30.00 | 4 | 42.50 | 4 (0%) | 38.20 | 4 (0%) | 49.60 | 3 (25%) | 31.867 | <0.001** | |
| H value | 1.283 | 42.45 | 32.97 | 45.75 | ||||||||
| Sig | 0.527 NS | <0.001** | <0.001** | <0.001** | ||||||||
Intergroup comparison of pain scores
**Statistically highly significant (p < 0.01); NS, not significant (p > 0.05)
| Group | N | Baseline | Dentin | Pulp | Debridement | ||||
| Z value | Sig | Z value | Sig | Z value | Sig | Z value | Sig | ||
| Ketorolac Group vs Ibuprofen Group | 20 | -1.122 | 0.429 NS | -5.048 | <0.001** | -0.644 | 0.583 NS | -3.407 | 0.006** |
| Ketorolac group vs Placebo Group | 20 | -0.781 | 0.602 NS | -5.196 | <0.001** | -2.639 | 0.023* | -5.946 | <0.001** |
| Ibuprofen group vs Placebo group | 20 | -0.350 | 0.799 NS | -1.964 | 0.108 NS | -2.257 | 0.060 NS | -5.323 | <0.001** |